MAM
KNSA icon

Martingale Asset Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Martingale Asset Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8,100
Closed -$315K – 809
2025
Q3 		$315K Sell
8,100
-44,334
-85% -$1.44M 0.01% 686
2025
Q2 		$1.45M Buy
52,434
+2,434
+5% +$62K 0.04% 376
2025
Q1 		$1.11M Buy
50,000
+640
+1% +$13.2K 0.03% 434
2024
Q4 		$976K Buy
49,360
+900
+2% +$20.5K 0.02% 476
2024
Q3 		$1.21M Buy
48,460
+3,083
+7% +$75.1K 0.03% 418
2024
Q2 		$847K Hold
45,377
– – 0.02% 485
2024
Q1 		$895K Hold
45,377
– – 0.02% 493
2023
Q4 		$796K Buy
45,377
+14
+0% +$230 0.02% 501
2023
Q3 		$788K Buy
45,363
+2
+0% +$34 0.02% 508
2023
Q2 		$639K Buy
45,361
+1,208
+3% +$16.2K 0.01% 563
2023
Q1 		$475K Buy
44,153
+1,001
+2% +$13.2K 0.01% 632
2022
Q4 		$646K Buy
43,152
+11
+0% +$160 0.01% 573
2022
Q3 		$554K Buy
43,141
+3,309
+8% +$37.7K 0.01% 598
2022
Q2 		$387K Buy
39,832
+2,817
+8% +$26.3K 0.01% 695
2022
Q1 		$369K Buy
37,015
+1,401
+4% +$14.8K 0.01% 699
2021
Q4 		$420K Sell
35,614
-200
-0.6% -$2.46K 0.01% 679
2021
Q3 		$409K Buy
35,814
+21,002
+142% +$274K 0.01% 703
2021
Q2 		$208K Hold
14,812
– – ﹤0.01% 798
2021
Q1 		$275K Sell
14,812
-100
-0.7% -$2.04K ﹤0.01% 765
2020
Q4 		$265K Sell
14,912
-48,600
-77% -$854K ﹤0.01% 768
2020
Q3 		$974K Sell
63,512
-24,095
-28% -$452K 0.01% 645
2020
Q2 		$2.23M Buy
+87,607
New +$1.83M 0.03% 494

Other funds holding KNSA

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Martingale Asset Management's KNSA Position: Q4 2025 in Review

Martingale Asset Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2025, closing a stake of 8,100 shares — an estimated $315K sold.

Martingale Asset Management first reported a position in KNSA in Q2 2020 and held it in 22 quarters. The position peaked at $2.23M in Q2 2020. 224 funds tracked by Wall St. Rank hold KNSA as of Q4 2025.

  • Martingale Asset Management reported no remaining Kiniksa Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Martingale Asset Management sold 8,100 Kiniksa Pharmaceuticals shares in Q4 2025, an estimated $315K.
  • Martingale Asset Management first reported a position in Kiniksa Pharmaceuticals in Q2 2020 and held it in 22 quarters.
  • Martingale Asset Management's Kiniksa Pharmaceuticals position peaked at $2.23M in Q2 2020.
  • 224 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2025.

Based on Martingale Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.